Page last updated: 2024-12-10

8,9-epoxyeicosatrienoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8,9-epoxyeicosatrienoic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

8,9-EET : An EET obtained by formal epoxidation of the 8,9-double bond of arachidonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283203
CHEMBL ID1437769
CHEBI ID34490
SCHEMBL ID2508714
MeSH IDM0144654

Synonyms (32)

Synonym
8,9-epoxyeicosatrienoic acid
(+/-)8,9-epetre
8,9-eet
8,9-epoxy-5z,11z,14z-eicosatrienoic acid
LMFA03080003
BSPBIO_001481
(5z,11z,14z)-8,9-epoxyicosa-5,11,14-trienoic acid
(5z,11z,14z)-8,9-epoxyeicosa-5,11,14-trienoic acid
IDI1_033951
NCGC00161266-01
NCGC00161266-02
NCGC00161266-03
HMS1989K03
(+/-)8,9-epoxyeicosa-5z,11z,14z-trienoic acid
8(9)-epetre
81246-85-7
BML1-D09
HMS1791K03
HMS1361K03
8,9-epoxy-5z,11z,14z-icosatrienoic acid
(5z)-7-{3-[(2z,5z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoic acid
CHEBI:34490 ,
SCHEMBL2508714
CHEMBL1437769
HMS3402K03
(5z,11z,14z)-8,9-epoxyicosa-5,11,14-trienoate
(5z,11z,14z)-8,9-epoxyeicosa-5,11,14-trienoate
8,9-epoxyeicosatrienoate
Q27104286
8,9-epoxy-5z,11z,14z-eicosatrienoate
8(9)-eet-[d11]
(+/-)8(9)-eet

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves (10(-9) to 10(-6) M) to 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, and ACh (10(-9) to 10(-4) M) were evaluated in preconstricted (10(-6) mol/l phenylephrine) mesenteric arteries (<350 microm diameter) in the presence or absence of 1) the cyclooxygenase inhibitor indomethacin (2."( Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase.
Abraham, NG; Bolognesi, M; Di Pascoli, M; Gatta, A; McGiff, JC; Sacerdoti, D; Schwartzman, ML, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
EETAn icosanoid obtained by formal epoxidation of one of the double bonds of arachidonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (46)

PathwayProteinsCompounds
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
Eicosanoid metabolism via cytochrome P450 monooxygenases pathway113
Arachidonic acid (AA, ARA) oxylipin metabolism076
Eicosanoid metabolism via cytochrome P450 monooxygenases213
Arachidonate epoxygenase / epoxide hydrolase09
Arachidonic acid metabolism via CYP (Cytochromoe P450) pathway014

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency0.19950.180013.557439.8107AID1468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (5.94)18.7374
1990's34 (33.66)18.2507
2000's37 (36.63)29.6817
2010's23 (22.77)24.3611
2020's1 (0.99)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.45 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.97%)5.53%
Reviews2 (1.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other100 (97.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]